- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05100043
Interleukin 4 and Interferon Gamma Predictors of Human Papillomavirus Immunotherapy in Warts
November 12, 2023 updated by: Noha M Hammad, MD, Zagazig University
IL-4 and IFN-γ as Immunologic Predictors of Response to HPV Immunotherapy in Warts
In the present study the investigators assessed the invitro role of IL-4 and IFN-γ in predicting the response to bivalent HPV vaccine after whole blood stimulation
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
40 Patients and 40 controls are enrolled in the study.
Participants suffer from chronic recurrent cutaneous and genital warts.
Blood samples were withdrawn then whole blood cultures are prepared.
Cultures are stimulated with bivalent HPVvaccine.
IL-4 and IFN-γ measurement in culture supernatants by ELISA.
IL-4 and IFN-γ are investigated to predict the therapeutic response to bivalent HPV vaccine immunotherapy in warts.
Study Type
Observational
Enrollment (Actual)
80
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Sharkia
-
Zagazig, Sharkia, Egypt, 44519
- Zagazig University Faculty of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Sampling Method
Probability Sample
Study Population
Patients are attendants in Zagazig University Hospitals Dermatology outpatient clinic
Description
Inclusion Criteria:
- Patients with recurrent and recalcitrant cutaneous and anogenital warts.
Exclusion Criteria:
- History of allergy to the HPV vaccine
- Active viral, fungal, or bacterial infections
- Immunosuppressive diseases or drugs.
- Autoimmune diseases, or other systemic diseases, e.g., hepatic, or renal disorders, diabetes, meningitis or convulsions
- Skin allergies
- Pregnancy and lactation
- Earlier wart treatment at least one month before enrollment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Cases
Patients having multiple recurrent and recalcitrant cutaneous and genital warts
|
Blood samples are withdrawn from participants and whole blood cultures are prepared and stimulated by bivalent HPV vaccine.IL-4 and IFN-γ are measured in culture supernatants
|
Controls
Healthy volunteers matched for age and sex
|
Blood samples are withdrawn from participants and whole blood cultures are prepared and stimulated by bivalent HPV vaccine.IL-4 and IFN-γ are measured in culture supernatants
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of IFN-γ and IL-4 levels
Time Frame: 48 hours
|
Quantitative measurement of IFN-γ and IL-4 in culture supernatants
|
48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the size of warts
Time Frame: 6 months
|
Clinical observation and photographing of wart size
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Ayman Marei, MD, PhD, Faculty of Medicine, Zagazig University , Zagazig, Egypt
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 3, 2020
Primary Completion (Actual)
July 3, 2020
Study Completion (Actual)
March 2, 2021
Study Registration Dates
First Submitted
October 5, 2021
First Submitted That Met QC Criteria
October 18, 2021
First Posted (Actual)
October 29, 2021
Study Record Updates
Last Update Posted (Estimated)
November 14, 2023
Last Update Submitted That Met QC Criteria
November 12, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Virus Diseases
- Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- DNA Virus Infections
- Skin Diseases, Infectious
- Papillomavirus Infections
- Skin Diseases, Viral
- Tumor Virus Infections
- Urogenital Diseases
- Genital Diseases
- Warts
- Condylomata Acuminata
Other Study ID Numbers
- 3140-23-10-2019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Warts Hand
-
Pulse Biosciences, Inc.CompletedWarts | Warts Hand | VerrucaUnited States
-
Pulse Biosciences, Inc.CompletedWarts | Warts Hand | VerrucaUnited States
-
Verrica Pharmaceuticals Inc.BioClinica, Inc.; Paidion Research, Inc.; Instat Consulting, Inc.; ALMAC Clinical...CompletedSkin Diseases | Virus Diseases | DNA Virus Infections | Skin Diseases, Infectious | Warts | Papillomavirus Infections | Skin Diseases, Viral | Tumor Virus Infections | Common Wart | Verruca Vulgaris | Warts Hand | VerrucaUnited States
-
RXi Pharmaceuticals, Corp.UnknownPlantar Warts | Common Warts | HPV (Human Papillomavirus) | Periungual WartsUnited States
-
Otto-Friedrich-University BambergUniversity of TurkuEnrolling by invitation
-
Christine M. Kleinert Institute for Hand and MicrosurgeryUniversity of Missouri-ColumbiaUnknownHand Transplant | Hand ReplantUnited States
-
McGill University Health Centre/Research Institute...CompletedAnesthesia, Local | Hand Injuries | Quality of Recovery | Hand Surgery | Hand Fracture | Hand Tendon InjuryCanada
-
University of ZurichWithdrawnHand Osteoarthritis | Wrist Injuries | Wrist Fracture | Hand Injury Wrist | Wrist Arthritis | Hand Fracture | Hand Sprain
-
Hôpital du ValaisCompletedHand InjurySwitzerland
-
Mayo ClinicCompletedInfection | Hand Injuries | Hand Injury Wrist | Hand Injuries and Disorders | Hand ArthritisUnited States
Clinical Trials on IL-4 and IFN-γ measurements
-
Vanderbilt University Medical CenterAmerican Heart AssociationNot yet recruitingLong COVID | Autonomic Dysfunction | POTS - Postural Orthostatic Tachycardia Syndrome
-
Huntington Medical Research InstitutesInterMuneUnknown
-
Hospital Universitari de BellvitgeInstituto de Salud Carlos III; Spanish Society of CardiologyRecruitingCMV Infection | Heart Transplant InfectionSpain
-
Affiliated Hospital of Jiangnan UniversityWest China Hospital; Hunan Cancer Hospital; Shenzhen Second People's Hospital; Zhejiang... and other collaboratorsRecruitingPleural Effusion, MalignantChina
-
The First People's Hospital of ChangzhouNot yet recruiting
-
Fuzhou General HospitalUnknownRenal Cell CarcinomaChina
-
Sawa Ito, MDHorizon Pharma USA, Inc.CompletedMyelodysplastic Syndromes | Myeloid Leukemia | Allogeneic Stem Cell TransplantationUnited States
-
OncoCareClinic 308 LtdRecruiting
-
Massachusetts General HospitalSiemens Medical Solutions; Radiological Society of North America; Canon Medical...CompletedLiver Diseases | Liver FibrosisUnited States
-
Ascendis Pharma Oncology Division A/SRecruitingAdvanced Solid Tumor | Metastatic Solid Tumor | Platinum-resistant Ovarian Cancer | Locally Advanced Solid Tumor | Post Anti-PD-1 Melanoma | 2L+ Cervical Cancer | Neoadjuvant Melanoma | Neoadjuvant Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Small Cell...United States, Australia, Korea, Republic of